1. Home
  2. IPSC vs FOCL Comparison

IPSC vs FOCL Comparison

Compare IPSC & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

HOLD

Current Price

$1.44

Market Cap

268.0M

Sector

Health Care

ML Signal

HOLD

FOCL

EDAP TMS S.A. American Depositary Shares

SELL

Current Price

$4.30

Market Cap

222.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IPSC
FOCL
Founded
2019
1979
Country
United States
France
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.0M
222.4M
IPO Year
2021
1998

Fundamental Metrics

Financial Performance
Metric
IPSC
FOCL
Price
$1.44
$4.30
Analyst Decision
Buy
Buy
Analyst Count
5
5
Target Price
$4.75
★ $8.80
AVG Volume (30 Days)
★ 690.4K
73.4K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 91.30
N/A
EPS
★ N/A
N/A
Revenue
★ $109,164,000.00
$70,527,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$34.10
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 1556.76
1.63
52 Week Low
$0.44
$4.00
52 Week High
$2.97
$6.40

Technical Indicators

Market Signals
Indicator
IPSC
FOCL
Relative Strength Index (RSI) 34.68 48.98
Support Level $0.90 $4.01
Resistance Level $2.62 $4.63
Average True Range (ATR) 0.12 0.29
MACD -0.02 0.00
Stochastic Oscillator 31.43 40.86

Price Performance

Historical Comparison
IPSC
FOCL

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

About FOCL EDAP TMS S.A. American Depositary Shares

Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.

Share on Social Networks: